Overview
Company
Company Profile
Management
Our History
Great Place to Work
Science
Scientific Approach
Innate Immunity & NK Cells
Antibody Formats
Anket: Our NK Cell Engager Platform
Publications
Products
Pipeline Overview
Clinical Trials
Lacutamab
Monalizumab
Avdoralimab
IPH5201
IPH5301
IPH6101
IPH62
Partnering
Investors
Overview
News
Events
Stock Info
Share Information
Stock Quote & Chart
Analyst Coverage
Financials & Regulatory Information
Financial Reports
SEC Filings
Number of Shares and Voting Rights
Articles of Association
Share Repurchase Liquidity Agreement
Prospectus Related to Public Offering
Appraiser Reports
Regulated Agreements
General Shareholders' Meeting
Governance
Corporate Governance
Management Team
Resources
Investor Email Alerts
Media
Media Hub
All Press Releases
Media Center
Careers
Skip to main content
Français
Number of Shares and Voting Rights
Overview
Company
Company Profile
Management
Our History
Great Place to Work
Science
Scientific Approach
Innate Immunity & NK Cells
Antibody Formats
Anket: Our NK Cell Engager Platform
Publications
Products
Pipeline Overview
Clinical Trials
Lacutamab
Monalizumab
Avdoralimab
IPH5201
IPH5301
IPH6101
IPH62
Partnering
Investors
Overview
News
Events
Stock Info
Share Information
Stock Quote & Chart
Analyst Coverage
Financials & Regulatory Information
Financial Reports
SEC Filings
Number of Shares and Voting Rights
Articles of Association
Share Repurchase Liquidity Agreement
Prospectus Related to Public Offering
Appraiser Reports
Regulated Agreements
General Shareholders' Meeting
Governance
Corporate Governance
Management Team
Resources
Investor Email Alerts
Media
Media Hub
All Press Releases
Media Center
Careers
Selecting the value will change the page content
Select Year:
Loading...